Back to CVE records
High 8.5Published Sep 17, 2026

CVE-2026-92958vm2 before 3.11.7 Denylist Bypass via fs/promises

Updated under an hour ago ()

Does this affect you?

It affects patriksimek vm2. Add what you run to find out whether that includes you.

No exploitation reported and no EPSS estimate yet.

vm2 through 3.11.6 contains a builtin-module denylist bypass in NodeVM. When the embedder uses the builtin wildcard together with negative entries (e.g. require: { builtin: ['*', '-fs', '-child_process'] }), negative entries are matched by exact module name in lib/builtin.js, so -fs removes only the builtin named fs and does not remove builtin subpaths such as fs/promises. Sandboxed code can therefore call require('fs/promises') or require('node:fs/promises') and reach the promise-based filesystem API despite fs being denied; node: prefix handling is likewise inconsistent (a -node:fs/promises entry does not block require('fs/promises')). Host file creation and writing were confirmed via fsp.writeFile(), and other fs/promises operations (cp, mkdir, rename, rm, rmdir, truncate, read operations, etc.) are also reachable. This issue is fixed in vm2 3.11.7.

CVSS
8.5 HIGH (v3.1, CNA)CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:N/I:H/A:L
Weakness (CWE)
CWE-269
Known exploited
Not in CISA's KEV catalog
EPSS (exploitation in the next 30 days)
Not loaded for this CVE
Assigned by
VulnCheck
NVD analysis
Deferred
Record last updated
Sep 18, 2026
First seen by InfoSec Signals
Oct 9, 2026

Affected products

Affected products
patriksimek vm2
patriksimek:vm2 (from the name)
before 3.11.7; 3.11.7 not affected
CNA record

References

  • vendor-advisory
  • third-party-advisory

The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.

Your cookie choices
We use essential cookies to run this site, and, only with your consent, an advertising cookie from Google to measure whether our ads lead to sign-ups and subscriptions. See our for details.